Changes in iron content in brain structures during aging and associated neurodegenerative diseases

Salkov, V N; Khudoyerkov, R M

doi:10.17116/patol20208205173

Cited by 3 publications

(1 citation statement)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Iron accumulation in the brain is common with aging and consistently reported to be increased in PD 5 , particularly in the substantia nigra 6 – 8 (and specifically the SNc 9 – 14 ). This accumulation has been suggested to contribute to dopaminergic neuron loss via multiple mechanisms.…”

Section: Introductionmentioning

confidence: 99%

Low plasma serotonin linked to higher nigral iron in Parkinson’s disease

Jellen

Lewis

et al. 2021

Sci Rep

View full text Add to dashboard Cite

A growing body of evidence suggests nigral iron accumulation plays an important role in the pathophysiology of Parkinson’s disease (PD), contributing to dopaminergic neuron loss in the substantia nigra pars compacta (SNc). Converging evidence suggests this accumulation might be related to, or increased by, serotonergic dysfunction, a common, often early feature of the disease. We investigated whether lower plasma serotonin in PD is associated with higher nigral iron. We obtained plasma samples from 97 PD patients and 89 controls and MRI scans from a sub-cohort (62 PD, 70 controls). We measured serotonin concentrations using ultra-high performance liquid chromatography and regional iron content using MRI-based quantitative susceptibility mapping. PD patients had lower plasma serotonin (p < 0.0001) and higher nigral iron content (SNc: p < 0.001) overall. Exclusively in PD, lower plasma serotonin was correlated with higher nigral iron (SNc: r(58) = − 0.501, p < 0.001). This correlation was significant even in patients newly diagnosed (< 1 year) and stronger in the SNc than any other region examined. This study reveals an early, linear association between low serotonin and higher nigral iron in PD patients, which is absent in controls. This is consistent with a serotonin-iron relationship in the disease process, warranting further studies to determine its cause and directionality.

show abstract

Section: Introductionmentioning

confidence: 99%

Low plasma serotonin linked to higher nigral iron in Parkinson’s disease

Jellen

Lewis

et al. 2021

Sci Rep

View full text Add to dashboard Cite

show abstract

The bs-YHEDA peptide protects the brains of senile mice and thus recovers intelligence by reducing iron and free radicals

Gao

Wang

Xiong

et al. 2022

Free Radical Biology and Medicine

View full text Add to dashboard Cite

Biomarkers of oxidative stress and proteopathies in the diagnosis of neurodegenerative diseases

Mikashinovich,

Telesmanich,

Smirnova

et al. 2024

Mol Med Rus

View full text Add to dashboard Cite

Introduction. Despite numerous studies in the field of neurodegenerative diseases, the exact mechanisms of these processes have not yet been identified. The purpose of this review is to analyze the methodological approaches necessary to revise the traditional and create new reliable prognostic and diagnostic algorithms that reflect pathogenetic features at different stages of neurodegeneration and atypical course of the disease. Material and methods. The review highlights the results of clinical and experimental studies obtained using a complex of clinical, laboratory and instrumental methods with an emphasis on markers of oxidative stress and proteopathy. In preparing the materials, sources from international and domestic databases were used: Scopus, Web of Science, Pub Medline, RSCI mainly for the last 15 years. Results. An idea has been formed about the molecular mechanisms of neural tissue regression in a number of neurodegenerative diseases such as multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer’s and Parkinson’s disease. The relationship between the parameters of the oxidative process and the features of metal-energy shifts in organs and organ systems is demonstrated. The role of markers of oxidative stress in the early stages, when the process of inflammation prevails and in the atypical course of the disease, is shown. Valuable biochemical markers are cytokines, glutathione levels, myeloperoxidase activation, and isoprostanes. The review points to the prospect of including in screening indicators of iron and other metals such as Zn, Mg, affecting the clinic accumulation of β-amyloid, in connection with which they can be considered as the basis for the progression of neurodegeneration. New data on the contribution of halogenating stress to the pathogenesis of neuroinflammation are presented. An aspect requiring development in the field of biomarkers for assessing the duration of the disease and prognostic prospects is the data on the correlation of metabolic shifts in the intestinal microbiota with the duration of the disease and the inflammatory process. Essential for the creation of express diagnostic methods is the determination of redox balance as an integral marker in saliva, which has obvious advantages over the use of biological fluids, such as liquor and serum. Conclusion. The prospects of creating new prognostic and diagnostic schemes are associated with complexes, including laboratory and instrumental methods, in blood, liquor and saliva. Evaluation of the sensitivity and specificity of new markers depending on the clinical diagnosis allows the selection of pathogenetically significant markers in the early stages of the disease, with atypical neurodegeneration, to establish subtypes of the disease, to carry out their differential diagnosis.

show abstract

Changes in iron content in brain structures during aging and associated neurodegenerative diseases

Cited by 3 publications

References 49 publications

Low plasma serotonin linked to higher nigral iron in Parkinson’s disease

Low plasma serotonin linked to higher nigral iron in Parkinson’s disease

The bs-YHEDA peptide protects the brains of senile mice and thus recovers intelligence by reducing iron and free radicals

Biomarkers of oxidative stress and proteopathies in the diagnosis of neurodegenerative diseases

Contact Info

Product

Resources

About